The Trump administration has announced plans to revisit a policy designed to close a loophole in Medicare's drug price negotiation process. The proposed rule targets a gap that experts say has undermined the program's ability to secure lower prices for seniors. Officials have not yet released a timeline for the new rulemaking.
Medicare's drug price negotiation program, established under the Inflation Reduction Act, allows the government to negotiate prices for certain high-cost medications. Critics have long argued that a loophole enables drugmakers to avoid full participation by manipulating patent or exclusivity periods. This effort marks a renewed focus on pharmaceutical pricing by the administration.
According to STAT News, the proposed rule would apply to a subset of medications currently exempt from negotiation. The administration estimates the change could affect spending on several top-selling drugs, though specific financial projections were not provided in the announcement. Industry stakeholders are expected to challenge the move.
If enacted, the policy could lower out-of-pocket costs for Medicare beneficiaries and reduce federal spending. Drug manufacturers warn that narrower negotiation authority may stifle innovation and limit patient access to new therapies. The public comment period will likely draw intense lobbying from both sides.
The administration's move signals a continued push for drug pricing reforms, even amid broader political battles over healthcare costs.